By Reuters | December 27, 2006

WASHINGTON -- Cyberonics Inc.'s shares fell over 8 percent yesterday after the Food and Drug Administration said the company will update an advisory panel next month on post-marketing studies of its implanted device to treat depression.


The FDA called for the studies as a condition of its July 2005 approval for the additional use of the VNS Therapy device, which was already cleared to treat epilepsy.

Dr. Daniel Schultz, head of FDA's Center for Devices and Radiological Health, said the agency was calling for the Jan. 26 public review in an effort to make sure such post-marketing studies are completed

FULL STORY :Click Below

http://www.boston.com/business/globe/artic..._to_get_review/

I don't think they will make the January 26th deadline. My psychiatrist has about 20 of the test study group people. One was implanted Friday, another will be implanted this week, there are others already done, but by no more than 5 months.

In his own practice he is having over an 80% success rate. He treats all types of depression, but other psychiatrist hand over their patient's to him when they become frustrustrated with no respose ( as I was ). Most of his patient's are TRD.

Labrat :im_033: